Fusion Antibodies Plc (GB:FAB) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Fusion Antibodies Plc has announced an expansion of their collaboration with the National Cancer Institute to include the humanisation of camelid nanobodies, which shows promise for CAR-T therapy applications. The company, known for its work in pre-clinical antibody discovery and engineering, aims to support the NCI in advancing these therapies toward clinical success. Fusion Antibodies, established in 2001 and listed on AIM since 2017, offers a suite of services to aid in the development of therapeutic drugs and diagnostic applications.
For further insights into GB:FAB stock, check out TipRanks’ Stock Analysis page.
